# LIRAGLUTIDE: Clinical Guide for Practices > Liraglutide is a GLP-1 receptor agonist FDA-approved for weight management (Saxenda, 3mg daily) and type 2 diabetes (Victoza, 1.8mg daily). As a daily injection, it offers an alternative to weekly semaglutide for patients who prefer more frequent but lower-peak dosing, or who experience side effects with weekly formulations. Compounded versions are available. **FDA compounding category:** FDA-approved (Saxenda/Victoza); compounding eligibility tied to shortage status. Verify current classification before prescribing **Category:** Weight Loss & Metabolic **Route of administration:** Subcutaneous injection (daily) ## Mechanism of action Liraglutide is a GLP-1 analog with 97% homology to native GLP-1, modified with a C-16 fatty acid chain that enables albumin binding and extends half-life to approximately 13 hours (compared to 2 minutes for native GLP-1) [4]. It activates hypothalamic GLP-1 receptors to reduce appetite, stimulates glucose-dependent insulin secretion from pancreatic beta cells, and delays gastric emptying [1]. The daily dosing produces less pronounced peak-trough fluctuations compared to weekly formulations. ## Evidence summary The SCALE Obesity and Prediabetes trial demonstrated 8.0% mean body weight reduction at 56 weeks with liraglutide 3mg daily versus 2.6% with placebo [1]. The LEADER cardiovascular outcomes trial showed a 13% reduction in major adverse cardiovascular events in patients with type 2 diabetes [3]. FDA approved liraglutide for chronic weight management (Saxenda) in December 2014 [2], making it the first GLP-1 agonist approved for obesity. Long-term safety data exceeds 10 years of clinical experience, providing the most extensive safety profile among GLP-1 weight loss medications [4]. ## Patient selection Good candidates include patients who experience intolerable side effects with weekly GLP-1 formulations (daily dosing allows faster dose adjustment), those who prefer a more gradual pharmacokinetic profile, or patients new to GLP-1 therapy who want a gentler introduction [4]. Also appropriate for adolescents aged 12+ with obesity (FDA-approved indication) [2]. Screen for personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Evaluate for pancreatitis history and gallbladder disease before initiation [3]. ## Clinical uses - Chronic weight management (FDA-approved as Saxenda at 3mg daily) - Type 2 diabetes glycemic control (FDA-approved as Victoza) - Cardiovascular risk reduction in patients with established CVD - Appetite regulation and caloric intake reduction ## Protocols and dosing Administered via daily subcutaneous injection with dose titration over 4-5 weeks. Weight loss protocol: start 0.6mg daily, increase by 0.6mg weekly to target dose of 3mg daily. Diabetes protocol targets 1.2-1.8mg daily. Weight management titration per FDA labeling: 0.6mg daily for week 1, 1.2mg for week 2, 1.8mg for week 3, 2.4mg for week 4, 3.0mg daily maintenance from week 5 [4]. If patients cannot tolerate dose escalation, hold at current dose for an additional week before advancing. Discontinue if patient has not achieved at least 4% weight loss by 16 weeks at full dose [2]. For diabetes (Victoza), target 1.2-1.8mg daily. Dosing flexibility is a key advantage; reduce dose immediately if GI intolerance develops. ## Side effects to monitor - Nausea (39% incidence; most common during titration, improves with time) - Diarrhea, constipation, and vomiting (common during dose escalation) - Headache and dizziness (mild, typically transient) - Pancreatitis (rare but serious; discontinue and do not restart if confirmed) - Gallbladder events including cholelithiasis (associated with rapid weight loss) ## Clinical considerations Daily injection (vs weekly for semaglutide/tirzepatide) may reduce patient adherence but allows faster dose adjustment,GI side effects common during titration (nausea, vomiting, diarrhea); slow titration improves tolerability,Same class contraindications: personal/family history of medullary thyroid carcinoma, MEN 2 syndrome,Monitor for pancreatitis symptoms and gallbladder disease,Compounding eligibility depends on FDA shortage status; verify current availability ## Practice economics Liraglutide programs are positioned as an accessible GLP-1 option with lower monthly costs than semaglutide or tirzepatide, typically $200-400 per month for compounded formulations. The extensive safety record [3] and FDA-approved adolescent indication [2] create differentiation opportunities. Practices can offer liraglutide as a first-line option or as a step-down for patients completing intensive semaglutide programs. ## Frequently asked questions ### When should liraglutide be chosen over semaglutide? Liraglutide may be preferred when patients experience intolerable side effects with weekly semaglutide (the daily dosing allows faster dose reduction), when a more gradual GLP-1 effect is desired, when weekly formulations are unavailable, or as a stepping stone before transitioning to weekly agents. Some patients also prefer the perceived control of daily dosing. ### How does liraglutide weight loss compare to semaglutide? Clinical trials show semaglutide 2.4mg weekly produces greater weight loss (approximately 15% body weight) than liraglutide 3mg daily (approximately 8% body weight). However, liraglutide has a longer clinical track record, more safety data, and some patients achieve adequate results without needing the more potent weekly agents. ### What is the transition protocol from liraglutide to semaglutide? There is no established direct conversion. Common clinical practice is to discontinue liraglutide, wait 24-48 hours (given liraglutide's 13-hour half-life), then initiate semaglutide at the lowest dose (0.25mg weekly) with standard titration. Do not overlap the two GLP-1 agonists. Monitor for GI tolerability during the transition. ## Sources - [Pi-Sunyer et al. - Liraglutide 3.0mg for Weight Management (SCALE Obesity, NEJM 2015)](https://pubmed.ncbi.nlm.nih.gov/26132939/) - [FDA Approval of Saxenda (liraglutide 3mg) for Chronic Weight Management](https://www.fda.gov/news-events/press-announcements/fda-approves-weight-management-drug-patients-aged-12-and-older) - [Marso et al. - Liraglutide and Cardiovascular Outcomes (LEADER Trial, NEJM 2016)](https://pubmed.ncbi.nlm.nih.gov/27295427/) - [Saxenda (liraglutide) Prescribing Information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206321s011lbl.pdf) --- Canonical page: https://karpahealth.com/resources/peptides/liraglutide/ Markdown version of the HTML page "liraglutide" at that URL. Machine-readable context: https://karpahealth.com/llms.txt · Pricing: https://karpahealth.com/pricing.md · Agents & API: https://karpahealth.com/agents.md